Publications by authors named "Maher Issa"

Claim this Profile
C
Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Peter C Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Maher Issa

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Thomas Bieber, Norito Katoh, Eric L Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Maher Issa

J Dermatolog Treat· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degradation of Azo Dye Solutions by a Nanocrystalline Fe-Based Alloy and the Adsorption of Their By-Products by Cork.
Wael Ben Mbarek, Maher Issa, Victoria Salvadó, Lluisa Escoda, Mohamed Khitouni

Materials (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials.
Andreas Wollenberg, Leon Kircik, Eric Simpson, Dennis Brinker, Norito Katoh, Maher Issa

Dermatitis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Thomas Bieber, Eugen Feist, Alan D Irvine, Masayoshi Harigai, Ewa Haladyj, Maher Issa

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.
Eric Morand, Josef S Smolen, Michelle Petri, Yoshiya Tanaka, Maria Silk, Maher Issa

RMD Open· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Peter C Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Maher Issa

Adv Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Thomas Bieber, Eugen Feist, Alan D Irvine, Masayoshi Harigai, Ewa Haladyj, Maher Issa

Adv Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arabian Levantine viper bite induces thrombocytopenia - a case report.
Ayman Abukamar, Rawan Abudalo, Mazen Odat, Mohammad Al-Sarayreh, Maher Bani Issa

J Med Life· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Peter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, Patrick Durez, Josef S Smolen, Maher Issa

Ann Rheum Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
Brett King, Catherine Maari, Edward Lain, Jonathan I Silverberg, Maher Issa

Am J Clin Dermatol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Kevin L Winthrop, Masayoshi Harigai, Mark C Genovese, Stephen Lindsey, Tsutomu Takeuchi, Maher Issa

Ann Rheum Dis· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.
Jonathan Kay, Masayoshi Harigai, Josh Rancourt, Christina Dickson, Thomas Melby, Maher Issa

RMD Open· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
Roy Fleischmann, Tsutomu Takeuchi, Michael Schiff, Douglas Schlichting, Li Xie, Maher Issa

Arthritis Care Res (Hoboken)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
Mark C Genovese, Josef S Smolen, Tsutomu Takeuchi, Gerd Burmester, Dennis Brinker, Maher Issa

Lancet Rheumatol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, Kevin L Winthrop, Atsushi Nishikawa, Maher Issa

Mod Rheumatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Peter C Taylor, Michael E Weinblatt, Gerd R Burmester, Terence P Rooney, Sarah Witt, Maher Issa

Arthritis Rheumatol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Yoshiya Tanaka, Bruno Fautrel, Edward C Keystone, Robert A Ortmann, Li Xie, Maher Issa

Ann Rheum Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
Kevin L Winthrop, Clifton O Bingham, Wendy J Komocsar, John Bradley, Maher Issa

Arthritis Res Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
Yoshiya Tanaka, Iain B McInnes, Peter C Taylor, Nicole L Byers, Lei Chen, Maher Issa

Arthritis Rheumatol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of complementary and alternative medicine by patients with cancer in Saudi Arabia.
Abdul Rahman Jazieh, Reem Al Sudairy, Omalkhair Abulkhair, Ahmed Alaskar, Faisal Al Safi, Maher Issa

J Altern Complement Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70.
Yan Li, Qiang Li, Cheng-jiang Li, Chang-jiang Wang, Yi-man Zheng, Maher Issa

Chin Med J (Engl)· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Guillermo Umpierrez, Maher Issa, Aleksandra Vlajnic

Curr Med Res Opin· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Victor Lawrence Roberts, John Stewart, Maher Issa, Barbara Lake, Robert Melis

Clin Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis